Aptus Capital Advisors LLC Increases Stock Holdings in Cencora, Inc. $COR

Key Points

• Aptus Capital Advisors LLC increased its stake in Cencora, Inc. by 39.7% in Q1, now owning shares valued at approximately $1.03 million.
• Wall Street analysts show optimism, with Wells Fargo raising the target price to $354 and a consensus rating of "Moderate Buy" for the stock.
• Cencora recently reported quarterly earnings with an EPS of $4.00, beating estimates, and announced a quarterly dividend of $0.55 per share.

Aptus Capital Advisors LLC grew its holdings in Cencora, Inc. (NYSE:COR - Free Report) by 39.7% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 3,699 shares of the company's stock after purchasing an additional 1,052 shares during the quarter. Aptus Capital Advisors LLC's holdings in Cencora were worth $1,029,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Exchange Traded Concepts LLC raised its stake in shares of Cencora by 4.5% during the 1st quarter. Exchange Traded Concepts LLC now owns 1,104 shares of the company's stock worth $307,000 after acquiring an additional 48 shares in the last quarter. Dynamic Advisor Solutions LLC grew its position in Cencora by 6.4% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 1,535 shares of the company's stock worth $427,000 after purchasing an additional 93 shares during the last quarter. GAMMA Investing LLC grew its position in Cencora by 57.0% during the 1st quarter. GAMMA Investing LLC now owns 5,748 shares of the company's stock worth $1,598,000 after purchasing an additional 2,087 shares during the last quarter. Golden State Wealth Management LLC grew its position in Cencora by 157.6% during the 1st quarter. Golden State Wealth Management LLC now owns 170 shares of the company's stock worth $47,000 after purchasing an additional 104 shares during the last quarter. Finally, Leith Wheeler Investment Counsel Ltd. grew its position in Cencora by 5.2% during the 4th quarter. Leith Wheeler Investment Counsel Ltd. now owns 82,952 shares of the company's stock worth $18,638,000 after purchasing an additional 4,126 shares during the last quarter. Institutional investors own 97.52% of the company's stock.

Cencora Price Performance

NYSE:COR traded down $4.3970 during trading hours on Monday, reaching $288.2030. 1,281,694 shares of the company were exchanged, compared to its average volume of 1,563,083. The company has a current ratio of 0.90, a quick ratio of 0.53 and a debt-to-equity ratio of 3.64. The stock's 50-day moving average is $293.48 and its 200-day moving average is $280.87. The firm has a market cap of $55.88 billion, a PE ratio of 29.65, a price-to-earnings-growth ratio of 1.39 and a beta of 0.58. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $309.35.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 earnings per share for the quarter, topping analysts' consensus estimates of $3.79 by $0.21. The company had revenue of $80.66 billion during the quarter, compared to analysts' expectations of $80.34 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm's revenue for the quarter was up 8.7% on a year-over-year basis. During the same period in the prior year, the business posted $3.34 earnings per share. On average, sell-side analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, August 15th will be given a dividend of $0.55 per share. The ex-dividend date is Friday, August 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.8%. Cencora's dividend payout ratio is currently 22.63%.

Insider Transactions at Cencora

In other news, Chairman Steven H. Collis sold 14,578 shares of the stock in a transaction dated Tuesday, July 22nd. The shares were sold at an average price of $292.67, for a total value of $4,266,543.26. Following the completion of the sale, the chairman directly owned 309,913 shares in the company, valued at $90,702,237.71. This represents a 4.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Robert P. Mauch sold 4,968 shares of the stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $294.11, for a total transaction of $1,461,138.48. Following the completion of the sale, the chief executive officer owned 42,351 shares of the company's stock, valued at $12,455,852.61. This trade represents a 10.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 34,125 shares of company stock valued at $9,993,789 over the last quarter. Company insiders own 10.80% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Morgan Stanley set a $330.00 price objective on shares of Cencora and gave the company an "equal weight" rating in a report on Wednesday, July 16th. Robert W. Baird upped their price objective on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Wells Fargo & Company upped their price objective on shares of Cencora from $337.00 to $354.00 and gave the company an "overweight" rating in a report on Wednesday, August 13th. UBS Group upped their price objective on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. Finally, Citigroup boosted their target price on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Cencora has an average rating of "Moderate Buy" and an average target price of $311.25.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.